Market Overview

Eton Pharmaceuticals Shares Slammed After FDA Complete Response Letter

Eton Pharmaceuticals Shares Slammed After FDA Complete Response Letter

Eton Pharmaceuticals (NASDAQ: ETON) shares are trading lower after the U.S Food and Drug Administration sent a Complete Response Letter to the company for EM-100. The news first hit wires after Friday's closing bell.

According to Eton, no concerns were raised about the clinical data in the application, "so it is not anticipated that any additional clinical work will be required."

“We believe the issues cited in the CRL can be addressed in the coming months, and we remain confident that EM-100 will be available to patients as quickly as possible,” said CEO Sean Brynjelsen.

Eton Pharmaceuticals shares were trading down 15.13% at $7.04 on Monday. The stock has a 52-week high of $10.20 and a 52-week low of $5.70.

Related Links:

Zosano Pharma Presents Positive Migraine-ACT Results

Fresh Del Monte Shares Fall Amid FDA Probe Following Outbreak Of Salmonella


Related Articles (ETON)

View Comments and Join the Discussion!

Posted-In: News FDA Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at